This volume provides the current understanding of death
receptor's/TLR3 signaling regulation in cancer. Death receptors,
including TRAIL-R1, TRAIL-R2, Fas and TNF-RI, owing to their
ability to trigger apoptosis and to contribute to the elimination
of cancer cells by the immune system have been considered, to
variable extent, as important therapeutic targets for cancer
therapy. But an increasing body of evidence suggests that some of
these receptors may also contribute to tumorigenesis, or that new
players such as TLR3 may be targeted for cancer therapy due to
their ability to behave like death receptors.
General
| Imprint: |
Springer International Publishing AG
|
| Country of origin: |
Switzerland |
| Series: |
Resistance to Targeted Anti-Cancer Therapeutics, 12 |
| Release date: |
July 2017 |
| First published: |
2017 |
| Editors: |
Olivier Micheau
|
| Dimensions: |
235 x 155mm (L x W) |
| Format: |
Hardcover
|
| Pages: |
317 |
| Edition: |
1st ed. 2017 |
| ISBN-13: |
978-3-319-56804-1 |
| Categories: |
Books >
Medicine >
Clinical & internal medicine >
Diseases & disorders >
Oncology >
General
|
| LSN: |
3-319-56804-3 |
| Barcode: |
9783319568041 |
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
Welcome to Loot.co.za!
Sign in / Register |Wishlists & Gift Vouchers |Help | Advanced search
